



*See Paper #4 #17 3/29/96*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of :

Robert M. LORENCE ET AL. :

Group Art Unit: 1813

Serial No.: 08/260,536 :

Examiner: L. Scheiner

Filed: June 16, 1994 :

For: **METHODS FOR TREATING AND DETECTING CANCER  
USING VIRUSES**

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

I hereby certify that this correspondence is being deposited  
with the U.S. Postal Services as First Class Mail in an envelope  
addressed To: Commissioner of Patents and Trademarks,  
Washington, D.C. 20231 On: 18 March 1996  
Name: Richard Lebowitz  
Signature: [Signature]  
Date: 18 March 1996

SIR:

The following documents, which are also listed on the attached PTO Form 1449,  
are submitted for the examiner's consideration:

U.S. 5,124,148

WO 86/00529

WO 86/00811

WO 93/18790

WO 94/21798

Eaton et al., "Contribution of Antiviral Immunity to Oncolysis by New-  
castle Disease Virus in a Murine Lymphoma," Journal of the Na-  
tional Cancer Institute, 39(6):1089-1097 (1967)

Webb et al., "Viruses in the Treatment of Cancer," The Lancet, pp. 1206-  
1208 (June 6, 1970)


- Beverley et al., "Immune Responses in Mice to Tumour Challenge After Immunization with Newcastle Disease Virus-Infected or X-Irradiated Tumour Cells or Cell Fractions," *Int. J. Cancer*, 11:212-223 (1973)
- Bart et al., "Role of Interferon in the Anti-Melanoma Effects of Poly(I).Poly(C) and Newcastle Disease Virus," *Nature New Biology*, 245 (147):229-230 (October 24, 1973)
- Eaton et al., "Autoimmunity Induced by Injection of Virus-Modified Cell Membrane Antigens in Syngeneic Mice," *Infection and Immunity*, 15(1):322-328 (January 1977)
- Huang et al., Studies on Viral Immunotherapy of Ascitic Tumors in Mice. I. Results of Treatment with Virus on Ehrlich and S<sub>180</sub> Ascitic Tumor Cells," *Acta Academiae Medicinae Sinicae*, 6(3):213-216 (June 1984)
- Fenglan et al., Studies on Combined Treatment of Cyclophosphamide and Virus in Mice Transplanted with S180 Ascitic Tumor Cells," *Acta Academiae Medicinae Sinicae*, 7(5):376-379 (October 1985)
- Shoham et al., "Augmentation of Tumor Cell Immunogenicity by Viruses - An Approach to Specific Immunotherapy of Cancer," *Nat. Immun. Cell Growth Regul.*, 9:165-172 (1990)
- Liebrich et al., "*In vitro* and Clinical Characterisation of a Newcastle Disease Virus-modified Autologous Tumour Cell Vaccine for Treatment of Colorectal Cancer Patients," *Eur. J. Cancer*, 27(6):703-710 (1991)
- Cassel et al., "A Ten-Year Follow-Up on Stage II Malignant Melanoma Patients Treated Postsurgically with Newcastle Disease Virus Oncolysate," *Med. Oncol. & Tumor Pharmacother.*, 9(4):169-171 (1992)
- Schirmacher et al., "Modulation of Cancer Cell Immunogenicity by Viral Gene or Cytokine Gene Transfection and Clinical Application of Virus Modified Cancer Vaccines," *Clinical & Experimental Metastasis*, Vol. 10, Suppl. 1, p. 68 (August 1992)
- Sinkovics et al., "New Developments in the Virus Therapy of Cancer: A Historical Review," *Intervirolgy*, 36:193-214 (1993)

This Information Disclosure Statement is being submitted after the mailing date of the final rejection (October 18, 1995), but before payment of the issue fee. It is hereby certified that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in any counterpart foreign application or, to the knowledge of the undersigned (after making reasonable inquiry), was known to any individual associated with the filing or prosecution of the above-identified

application more than three months prior to the filing of this Information Disclosure Statement.

Respectfully submitted,

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.



---

Richard M. Lebovitz (Reg. No. 37,067)  
Attorney for Applicants

Arlington Courthouse Plaza I  
2200 Clarendon Boulevard  
Suite 1400  
Arlington, VA 22201  
(703) 812-5317

Filed: March 18, 1996

RML:dm17:PROVI2.IDS